ArticleJournal of the Endocrine Society2025
Genetics Evaluation Outcomes From an Academic Multidisciplinary Atypical Diabetes Program.
Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epigenetic, Genetic, and Functional Germline Alterations ofCurrent issues in molecular biology · 2026Review
- Case Report: Familial partial lipodystrophy, description of novel and ultrarare variants with distinct phenotypic spectrum.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Rare monogenic conditions that predispose to diabetes can be misdiagnosed due to phenotypic overlap with more common conditions. Misdiagnosis can lead to ineffective, over-, or under-treatment. Specific genetic mechanisms can direct more precise treatment and facilitate clinical trial options. Recognition of characteristics of these conditions is necessary to facilitate high-yield referrals to genetics providers in order to improve diagnosis and treatment. Objective: Highlight clinical characteristics and diagnostic outcomes of patients undergoing genetics evaluation through a multidisciplinary Atypical Diabetes Program. Design Setting and Patients: Retrospective cohort review was completed for 87 patients referred to genetics from endocrinologists associated with the multidisciplinary Atypical Diabetes Program at a tertiary academic medical center between September 2019 and October 2022. Main Outcome Measure: Description of clinical characteristics of patients with a diagnostic or uncertain clinical genetic test result, as well as proportion of patients with these results. Results: Six patients (8.8%) had a pathogenic variant confirming diagnosis of lipodystrophy (4), monogenic diabetes (1), or monogenic obesity (1). Fifteen (22.0%) had a variant of uncertain significance, 5 of which correlated with their clinical features. As a result of genetics evaluation, all with a confirmed diagnosis had more precise treatment implemented and/or the opportunity to enroll in a clinical trial. Conclusion: Identification of rare genetic conditions predisposing to diabetes, enabled here through multidisciplinary genetics and endocrinology collaboration as part of the Atypical Diabetes Program, ultimately improves patient care. Endocrinologist attention to clinical features of these conditions is key to inform referral for genetics evaluation and testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.